Literature DB >> 28075068

Binding and processing of β-lactam antibiotics by the transpeptidase LdtMt2 from Mycobacterium tuberculosis.

Eva Maria Steiner1, Gunter Schneider1, Robert Schnell1.   

Abstract

β-lactam antibiotics represent a novel direction in the chemotherapy of tuberculosis that brings the peptidoglycan layer of the complex mycobacterial cell wall in focus as a therapeutic target. Peptidoglycan stability in Mycobacterium tuberculosis, especially during infection, relies on the nonconventional peptide cross-links formed by l,d-transpeptidases. These enzymes are known to be inhibited by β-lactams, primarily carbapenems, leading to a stable covalent modification at the enzyme active site. A panel of 16 β-lactam antibiotics was characterized by inhibition kinetics, mass spectrometry, and x-ray crystallography to identify efficient compounds and study their action on the essential transpeptidase, LdtMt2 . Members of the carbapenem class displayed fast binding kinetics, but faropenem, a penem type compound showed a three to four time higher rate in the adduct formation. In three cases, mass spectrometry indicated that carbapenems may undergo decarboxylation, while faropenem decomposition following the acylation step results in a small 87 Da β-OH-butyryl adduct bound at the catalytic cysteine residue. The crystal structure of LdtMt2 at 1.54 Å resolution with this fragment bound revealed that the protein adopts a closed conformation that shields the thioester bond from the solvent, which is in line with the high stability of this dead-end complex observed also in biochemical assays. DATABASE: Structural data are available in Protein Data Bank under the accession numbers 5LB1 and 5LBG.
© 2017 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Entities:  

Keywords:  covalent adduct; faropenem; l,d-transpeptidase; protein structure; β-lactam antibiotic

Mesh:

Substances:

Year:  2017        PMID: 28075068     DOI: 10.1111/febs.14010

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  12 in total

1.  Allosteric cooperation in β-lactam binding to a non-classical transpeptidase.

Authors:  Nazia Ahmad; Sanmati Dugad; Varsha Chauhan; Shubbir Ahmed; Kunal Sharma; Sangita Kachhap; Rana Zaidi; William R Bishai; Gyanu Lamichhane; Pankaj Kumar
Journal:  Elife       Date:  2022-04-27       Impact factor: 8.713

2.  T405, a New Penem, Exhibits In Vivo Efficacy against M. abscessus and Synergy with β-Lactams Imipenem and Cefditoren.

Authors:  Binayak Rimal; Hunter R Batchelder; Elizabeth Story-Roller; Chandra M Panthi; Chavis Tabor; Eric L Nuermberger; Craig A Townsend; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2022-05-31       Impact factor: 5.938

Review 3.  β-Lactam antibiotic targets and resistance mechanisms: from covalent inhibitors to substrates.

Authors:  Montserrat Mora-Ochomogo; Christopher T Lohans
Journal:  RSC Med Chem       Date:  2021-08-04

Review 4.  Have we realized the full potential of β-lactams for treating drug-resistant TB?

Authors:  Elizabeth Story-Roller; Gyanu Lamichhane
Journal:  IUBMB Life       Date:  2018-06-22       Impact factor: 3.885

5.  Structural insight into the inactivation of Mycobacterium tuberculosis non-classical transpeptidase LdtMt2 by biapenem and tebipenem.

Authors:  Mario A Bianchet; Ying H Pan; Leighanne A Brammer Basta; Harry Saavedra; Evan P Lloyd; Pankaj Kumar; Rohini Mattoo; Craig A Townsend; Gyanu Lamichhane
Journal:  BMC Biochem       Date:  2017-05-25       Impact factor: 4.059

Review 6.  Mycobacterium abscessus and β-Lactams: Emerging Insights and Potential Opportunities.

Authors:  Elizabeth Story-Roller; Emily C Maggioncalda; Keira A Cohen; Gyanu Lamichhane
Journal:  Front Microbiol       Date:  2018-09-25       Impact factor: 5.640

7.  Non-Hydrolytic β-Lactam Antibiotic Fragmentation by l,d-Transpeptidases and Serine β-Lactamase Cysteine Variants.

Authors:  Christopher T Lohans; H T Henry Chan; Tika R Malla; Kiran Kumar; Jos J A G Kamps; Darius J B McArdle; Emma van Groesen; Mariska de Munnik; Catherine L Tooke; James Spencer; Robert S Paton; Jürgen Brem; Christopher J Schofield
Journal:  Angew Chem Int Ed Engl       Date:  2019-01-21       Impact factor: 15.336

8.  A Fluorescence-Based Assay for Screening β-Lactams Targeting the Mycobacterium tuberculosis Transpeptidase LdtMt2.

Authors:  Mariska de Munnik; Christopher T Lohans; Gareth W Langley; Corentin Bon; Jürgen Brem; Christopher J Schofield
Journal:  Chembiochem       Date:  2019-11-08       Impact factor: 3.461

9.  Inhibiting Mycobacterium abscessus Cell Wall Synthesis: Using a Novel Diazabicyclooctane β-Lactamase Inhibitor To Augment β-Lactam Action.

Authors:  Khalid M Dousa; David C Nguyen; Sebastian G Kurz; Magdalena A Taracila; Christopher R Bethel; William Schinabeck; Barry N Kreiswirth; Sheldon T Brown; W Henry Boom; Richard S Hotchkiss; Kenneth E Remy; Frank J Jacono; Charles L Daley; Steven M Holland; Alita A Miller; Robert A Bonomo
Journal:  mBio       Date:  2022-01-25       Impact factor: 7.786

10.  Targeting the Mycobacterium tuberculosis transpeptidase LdtMt2 with cysteine-reactive inhibitors including ebselen.

Authors:  Mariska de Munnik; Christopher T Lohans; Pauline A Lang; Gareth W Langley; Tika R Malla; Anthony Tumber; Christopher J Schofield; Jürgen Brem
Journal:  Chem Commun (Camb)       Date:  2019-08-22       Impact factor: 6.065

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.